DexCom, Inc. (DXCM)
2 Growth Stocks to Buy and Hold for a Decade
Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid.
DexCom, Inc. (DXCM) Q1 2025 Earnings Call Transcript
DexCom, Inc. (NASDAQ:DXCM ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Sean Christensen - VP, Finance & IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & Chief Accounting Officer Jacob Leach - EVP & COO Conference Call Participants Matt Taylor - Jefferies Robbie Marcus - JPMorgan Danielle Antalffy - UBS Jeff Johnson - Baird Jayson Bedford - Raymond James Travis Steed - Bank of America Merrill Lynch Matt O'Brien - Piper Sandler Marie Thibault - BTIG Joanne Wuensch - Citibank Michael Polark - Wolfe Research Margaret Andrew - William Blair Mike Kratky - Leerink Partners Colin Clark - Stifel, Nicolaus & Company Issie Kirby - Redburn Bill Plovanic - Canaccord Chris Pasquale - Nephron Steve Lichtman - Oppenheimer & Co. Matt Miksic - Barclays Anthony Petrone - Mizuho Group Operator Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call.
Compared to Estimates, DexCom (DXCM) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
DexCom (DXCM) Q1 Earnings Miss Estimates
DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago.
Gear Up for DexCom (DXCM) Q1 Earnings: Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for DexCom (DXCM), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance
DXCM secures FDA clearance for its G7 15-Day CGM, the longest-lasting and most accurate wearable, enhancing user convenience and expanding diabetes care access.
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction
What should investors do during a market downturn? Some might resort to panic selling, but that's hardly a good strategy.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DXCM continues to raise investor optimism due to its strong product portfolio.
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
